Imjudo 25 mg/1.25 mL (20 mg/mL) injection Images
Generic Name: tremelimumab
This medication has been identified as Imjudo 25 mg/1.25 mL (20 mg/mL) injection. It is supplied by AstraZeneca.
Imjudo is used in the treatment of Hepatocellular Carcinoma; Non Small Cell Lung Cancer and belongs to the drug class anti-CTLA-4 monoclonal antibodies. Imjudo 25 mg/1.25 mL (20 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Imjudo
- Generic Name
- tremelimumab
- Strength
- 25 mg/1.25 mL (20 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-CTLA-4 monoclonal antibodies
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AstraZeneca
- National Drug Code (NDC)
- 00310-4505
See also:
Rybrevant
Rybrevant is used to treat advanced non-small cell lung cancer (NSCLC) in adults that has certain ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Lenvima
Lenvima (lenvatinib) is used to treat thyroid cancer, advanced renal cell carcinoma, hepatocellular ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Cabozantinib
Cabozantinib is used for hepatocellular carcinoma, neuroendocrine tumors, renal cell carcinoma ...
Lenvatinib
Lenvatinib is used to treat thyroid cancer, kidney cancer, liver cancer, and advanced endometrial ...
Durvalumab
Durvalumab (Imfinzi) is an immunotherapy used to treat lung cancer (NSCLC, SCLC) and other cancers ...
More about Imjudo (tremelimumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-CTLA-4 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.